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The anti-oestrogen drug tamoxifen is an inhibitor of lipid peroxidation in rat liver microsomes and in phospholipid liposomes. Its cis isomer and 
N-desmethyl form are weaker inhibitors, but 4-hydroxytamoxifen is much more powerful. It is possible that the antioxidant property of tamoxifen 
might contribute to its biological actions. 
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1. INTRODUCTION 
The anti-oestrogen drug tamoxifen (1-[4-(2-dimethyl- 
aminoethoxy)phenyl]-1,2-diphenylbut-1-ene, trans 
isomer), one of a series of synthetic triphenylethylene 
compounds, is widely used in the chemotherapy of 
breast cancer (reviewed in [l]) and has been proposed 
as a prophylactic agent against this disease. The anti- 
tumour activity of tamoxifen is believed to be largely 
due to its binding to oestrogen receptors, but there is 
also evidence for one or more additional mechanisms 
of action [1,2] including an ability to inhibit growth [3] 
and the synthesis of RNA and proteins (H.W., un- 
published data) in yeast cells, as well as to inhibit pro- 
tein synthesis in other eukaryotic cells [4] The cis 
isomer of tamoxifen has much less biological effect. In 
humans, tamoxifen is extensively metabolized to give 
4-hydroxytamoxifen and N-desmethyltamoxifen [5]. 
Their structures are shown in Fig. 1. 
Human breast tumour tissue shows differences in the 
rates of free radical reactions and in antioxidant protec- 
tion when compared to healthy breast tissue. These in- 
clude increases in superoxide dismutase activity [6], an 
ability to produce 0: and Hz02 from some anti-cancer 
drugs [7] and probably a decreased ability to undergo 
lipid peroxidation [8]. Indeed, changes in the rate of 
lipid peroxidation seem to be a general feature of 
cancerous cells and may be a prerequisite to cell divi- 
sion [g-13]. The carcinogenicity of the synthetic 
oestrogen diethylstilboestrol has been suggested to in- 
volve DNA damage caused by increased oxygen radical 
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formation [14]. By contrast, oestradiol, oestriol and 
oestrone have been reported to inhibit lipid peroxida- 
tion in vitro [ 15,161, as do their catechol metabolites 
[17]. In view of the amount of literature linking 
oestrogens, free radical reactions and tumour develop- 
ment [6-191, we thought it of interest to examine the 
action of tamoxifen and its metabolites on lipid perox- 
idation. The well-established rat liver microsomal 
system was used as a substrate, and peroxidation was 
started by adding iron(II1) and ascorbic acid [20]. 
Studies with NADPH-dependent peroxidation [21] are 
also reported for comparison. 
2. MATERIALS AND METHODS 
2.1. Preparation of microsomes 
Rat liver microsomes were prepared from the livers of adult male 
rats by standard differential centrifugation techniques as described in 
[22]. Liposomes were prepared from ox-brain phospholipids [22]. 
Tamoxifen and Ill-fi-oestradiol were purchased from Sigma. Purity 
was at least 99%. 4-Hydroxytamoxifen, N-desmethyltamoxifen and 
cis-tamoxifen were kindly supplied by ICI Pharmaceuticals ph. 
2.2. Lipid peroxidation 
Reaction mixtures contained in a final volume of 1.0 ml, 
microsomal fraction (0.25 mg microsomal protein), 10 mM 
KH2P04-KOH buffer pH 7.4 and 5 pl of ethanol or test compound 
dissolved in ethanol. Peroxidation was started by adding, to give the 
final concentrations stated, FeCl3 and ascorbate (both 1OOpM) or 
FeCls (lOOcM), ADP (1.7 mM) and NADPH (0.4 mM). The ADP 
and FeC13 were premixed before addition to the reaction mixture. 
Solutions of FeCl3, ADP and ascorbate were made up fresh im- 
mediately before use. Incubations were carried out at 37°C for 
20 min (unless otherwise stated). The amount of lipid peroxidation 
was measured by the formation of thiobarbituric acid-reactive 
substances (TBARS) as described in [22]. HCl(0.5 ml, 2.5% v/v) was 
added to each reaction mixture, followed by 0.5 ml of thiobarbituric 
acid solution (1% w/v in 50 mM sodium hydroxide). After heating 
at 80°C for 30 min the chromogen was extracted with 2 ml of 
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Fig. 1. Structure of tamoxifen and its derivatives. 
RI R2 
Tamoxifen H OCHzCHzN(CHr)z 
4-Hydroxytamoxifen OH OCHzCHzN(CHr)z 
Iv-Desmethyltamoxifen H OCHzCHzNHCH3 
butan-l-01 and Asr2 of the upper (organic) layer was measured. 
Peroxidation of liposomes induced by FeCI3 and ascorbic acid was 
measured as described above, except that microsomes were replaced 
by liposomes (1 mg/ml). 
3. RESULTS 
When Fe(II1) and ascorbic acid are added to rat liver 
microsomes at pH 7.4, rapid peroxidation occurs that 
can be measured by the TBA test [20]. Fig. 2 shows that 
tamoxifen inhibited the peroxidation to approximately 
the same extent as 17-,8-oestradiol. Cis-tamoxifen and 
N-desmethyltamoxifen were much less effective in- 
hibitors, whereas 4-hydroxytamoxifen was a much 
more powerful inhibitor of peroxidation. Table I lists 
loo- 
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Fig. 2. Concentration-dependent inhibition of microsomal lipid 
peroxidation induced by FeCIr and ascorbate. (0) Tamoxifen; (0) 
4-hydroxytamoxifen; (A) cis-tamoxifen; (A) N-desmethyltamoxifen; 
(m) 17-b-oestradiol. Results are mean + SD, n = 3-6. 
Table I 
ICse values for the inhibition of microsomal lipid peroxidation by 
tamoxifen, tamoxifen metabolites and 17-fl-oestradiol 
Compound ICso 01M) 
Fe(W)-ascorbate Fe(III)-ADP/NADPH 
system system 
Tamoxifen 12.5 20 
4-Hydroxytamoxifen 3.1 3.5 
cis-Tamoxifen 15.6 23.3 
N-Desmethyltamoxifen 17.5 25 
17-/3-Oestradiol 10.6 16 
Values are deduced from the graphs shown in Fig. 2, in which each 
point represents the mean + SD of 3-6 separate assays 
the I& values for the compounds tested. Tamoxifen 
and its metabolites inhibited peroxidation by an ap- 
proximately constant percentage throughout the course 
of the incubation (Fig. 3): there was no evidence for the 
‘lag period’, followed by an acceleration of peroxida- 
tion to the control rate, that is often observed when 
chain-breaking antioxidants are added to peroxidizing 
microsomes. None of the compounds tested interfered 
with the TBA test: no inhibition was seen when the 
compounds were added to peroxidizing microsomes 
with the TBA reagents instead of at the beginning of 
the incubation. The compounds were added dissolved 
in ethanol: the amount of ethanol present in our reac- 
tion mixtures had no significant effect on the rate of 
peroxidation. 
Microsomal peroxidation can also be started by addi- 
tion of Fe(III)-ADP and NADPH [21]. It was found 
08- 
07- 
06- 
05- 
4 
04- 
B 
03- 
02- 
l 
/ 
/ 
0 
0 5 10 15 20 
Time (m!n) 
Fig. 3. Time course of microsomal lipid peroxidation induced by 
FeClJ and ascorbate: the effect of tamoxifen and its derivatives added 
at their ICSO concentrations. (0) Control (ethanol only added); (0) 
12.5 yM tamoxifen; (A) 3.1 pM 4-hydroxytamoxifen; (A) 17.5 pM 
N-desmethyltamoxifen; (B) 15.6 ,uM cis-tamoxifen; (v) 10.6 yM 
17-,8-oestradiol. Concentrations quoted are the final concentrations 
in the reaction mixtures. 
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that tamoxifen, cis-tamoxifen, N-desmethyltamoxifen 
and 17-,8-oestradiol were weaker inhibitors of peroxida- 
tion in this enzyme-dependent system than when perox- 
idation was started with Fe(II1) and ascorbate (Table I), 
whereas 4-hydroxytamoxifen was approximately equal- 
ly effective. Table I summarizes the I&, values. It has 
been observed previously (e.g. [23,24]) that several an- 
tioxidants are less effective in the microsomal system 
when NADPH and Fe(III)-ADP are used to induce the 
peroxidation instead of ascorbic acid and Fe(II1). 
Tamoxifen and 4-hydroxytamoxifen were also found 
to inhibit the Fe(III)/ascorbate-induced peroxidation 
of a completely different lipid substrate, ox-brain 
phospholipid liposomes. ICSO values were 68 and 
6.3 PM, respectively. 
4. DISCUSSION 
17,8-Oestradiol has been claimed to be a potent in- 
hibitor of lipid peroxidation [15-171, a result confirm- 
ed in the present study. However, we have now shown 
that tamoxifen exerts a similarly potent effect in the 
microsomal system. 
Examination of the chemical structure of tamoxifen 
(Fig. 1) shows no apparent reason why it should act as 
a chain-breaking inhibitor of peroxidation, since there 
is no group bearing an easily donatable hydrogen atom. 
In any case, chain-breaking antioxidants usually in- 
troduce a lag period into the peroxidation time-course: 
this was not observed here. The cis- and N-desmethyl 
forms of tamoxifen were weaker inhibitors, which 
perhaps suggests that the conformation of the whole 
molecule is important and that it acts by modifying the 
structure of the microsomal and liposomal membranes 
so as to decrease the propagation rate of lipid peroxida- 
tion. The ability of various sterols and steroids to in- 
fluence membrane structure is well-established (e.g. 
[251). 
4-Hydroxytamoxifen was a much more powerful in- 
hibitor of lipid peroxidation than tamoxifen. It could 
be that the phenolic OH group confers chain-breaking 
antioxidant activity as well as the putative effects on 
membrane structure discussed above. The fact that 
tamoxifen and its metabolites will partition into mem- 
branes in vivo [26] suggests that their antioxidant ac- 
tivity might have physiological relevance. 
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